Characterizing phenotypes of acute heart failure
Characterisation of phenotYpes in aCute Heart faiLure patiEnts
This project will try to see if heart function measures, imaging features (radiomics), and blood biomarkers can predict outcomes for adults hospitalized with acute heart failure, including cardiogenic shock.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf Academic / other |
| Locations | 1 site (Hamburg) |
| Trial ID | NCT07508891 on ClinicalTrials.gov |
What this trial studies
This prospective, single-center observational cohort will enroll adults hospitalized with acute heart failure, including de novo cases, decompensated chronic heart failure, and all stages of cardiogenic shock. Researchers will collect functional clinical measures, radiological imaging with radiomics analysis, and circulating blood biomarkers, and will store biological samples in a biobank for future testing. The primary aim is to identify distinct patient phenotypes and combinations of biomarkers that improve individualized risk prediction. Results will generate hypotheses and candidate biomarkers to inform the design of future interventional trials.
Who should consider this trial
Good fit: Adults (age 18 and over) who are hospitalized with a clinical diagnosis of acute heart failure—including de novo presentations, decompensated chronic heart failure, or cardiogenic shock—and who can provide written informed consent are ideal candidates.
Not a fit: Children, outpatients with acute heart failure, patients unable to give written consent, and individuals not admitted to the study hospital are not eligible and therefore are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the findings could improve individualized risk prediction and help guide treatment decisions for patients hospitalized with acute heart failure.
How similar studies have performed: Previous cohort and biomarker studies have identified some prognostic markers in acute heart failure, but combining functional measures, radiomics, and prospective biobanking to define phenotypes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of acute heart failure, including all stages of cardiogenic shock, de novo heart failure as well as decompensated chronic heart failure. * Hospitalisation due to acute heart failure or new-onset acute heart failure during a hospitalisation de to a different cause. Out-patients with acute heart failure are not included. Exclusion Criteria: * Age \< 18 years * No written informed consent.
Where this trial is running
Hamburg
- University Medical Center Hamburg-Eppendorf — Hamburg, Germany (Recruiting)
Study contacts
- Study coordinator: Benedikt Schrage, MD, PhD
- Email: b.schrage@uke.de
- Phone: +49 40 7410 0
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.